Biotech · Public company · San Diego, CA, US
Cardiff Oncology, Inc.
Ticker CRDF · SEC CIK 0001213037
Track this companyFree. Adds Cardiff Oncology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials105 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline17
- AbirateronePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CytarabinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DecitabinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FluorouracilPhase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRIPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRIPhase 2 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- FOLFOXPhase 2 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- LeucovorinPhase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Nanoliposomal irinotecanPhase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- OnvansertibPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- OnvansertibPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- OnvansertibPhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- OnvansertibPhase 2 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- OnvansertibPhase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 17, 2025ClinicalTrials.gov NCT06736717 · fetched Nov 12, 2026
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 27, 2024ClinicalTrials.gov NCT06106308 · fetched Nov 12, 2026
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationPHASE2 · COMPLETED · started Mar 17, 2023ClinicalTrials.gov NCT05593328 · fetched Nov 12, 2026
- Onvansertib + Paclitaxel In TNBCPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 30, 2022ClinicalTrials.gov NCT05383196 · fetched Nov 12, 2026
- Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung CancerPHASE2 · RECRUITING · started Jul 19, 2022ClinicalTrials.gov NCT05450965 · fetched Nov 12, 2026
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaPHASE2 · TERMINATED · started May 25, 2021ClinicalTrials.gov NCT04752696 · fetched Nov 12, 2026
- Targeted Pathway Inhibition in Patients With Pancreatic CancerEARLY_PHASE1 · RECRUITING · started Aug 1, 2019ClinicalTrials.gov NCT04005690 · fetched Nov 12, 2026
- Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationPHASE1_PHASE2 · COMPLETED · started Jun 24, 2019ClinicalTrials.gov NCT03829410 · fetched Nov 12, 2026
- Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerPHASE2 · COMPLETED · started Aug 14, 2018ClinicalTrials.gov NCT03414034 · fetched Nov 12, 2026
- Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · COMPLETED · started Nov 17, 2017ClinicalTrials.gov NCT03303339 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Oct 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026